MediWound Pegs $1B Peak Sales for EscharEx in $4B Debridement Market
MDWD is trading near its 52-week low of $12.86 (3.3% above the low).
Summary
MediWound released new market research sizing the U.S. enzyme-based debridement market at roughly $4 billion by 2028, with pressure ulcers alone representing about $1 billion. The company now estimates annual peak U.S. sales potential for its investigational drug EscharEx at approximately $1.05 billion, up from prior assessments that excluded pressure ulcers. This follows the Q2 revenue decline and reaffirmed guidance reported on August 13, and the Phase III enrollment delay disclosed in May. The new figures are company-generated estimates, not confirmed sales, and EscharEx remains unapproved with pivotal data still pending. An investigator-initiated pressure ulcer trial is set to start late 2026, with Phase III VALUE trial enrollment completion expected by end of Q1 2027.
At the time of this announcement, MDWD was trading at $13.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $167.8M. The 52-week trading range was $12.86 to $20.30. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: FinanceWire.